Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (BCRX), Wave Life Sciences (WVE) and Alkermes (ALKS)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioCryst (BCRX – Research Report), Wave Life Sciences (WVE – Research Report) and Alkermes (ALKS – Research Report).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioCryst (BCRX)
Evercore ISI analyst Gavin Clark-Gartner reiterated a Hold rating on BioCryst yesterday and set a price target of $8.00. The company’s shares closed last Thursday at $7.16.
According to TipRanks.com, Clark-Gartner is a 5-star analyst with an average return of
BioCryst has an analyst consensus of Strong Buy, with a price target consensus of $19.45, which is a 170.5% upside from current levels. In a report issued on December 7, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $7.50 price target.
See Insiders’ Hot Stocks on TipRanks >>
Wave Life Sciences (WVE)
Wells Fargo analyst Tiago Fauth maintained a Buy rating on Wave Life Sciences yesterday and set a price target of $29.00. The company’s shares closed last Thursday at $15.82, close to its 52-week high of $16.74.
According to TipRanks.com, Fauth is a 5-star analyst with an average return of
Wave Life Sciences has an analyst consensus of Strong Buy, with a price target consensus of $32.43, representing a 98.3% upside. In a report issued on December 8, RBC Capital also upgraded the stock to Buy with a $27.00 price target.
Alkermes (ALKS)
Wells Fargo analyst Benjamin Burnett maintained a Buy rating on Alkermes yesterday and set a price target of $37.00. The company’s shares closed last Thursday at $28.14.
According to TipRanks.com, Burnett is a 1-star analyst with an average return of
Alkermes has an analyst consensus of Moderate Buy, with a price target consensus of $46.17, which is a 63.5% upside from current levels. In a report issued on December 3, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $33.00 price target.
